ArticleAsia Pacific allergy2026
The impact of public health emergencies on allergen immunotherapy practices: A cross-sectional study on COVID-19 and physicians' perspectives in China.
Article in Asia Pacific allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate how the COVID-19 pandemic transformed the clinical management of allergen-specific immunotherapy (AIT) in China and to establish an evidence-based AIT management strategy during future infectious disease outbreaks. Methods: This multicenter, cross-sectional survey was conducted in January 2025, involving 224 physicians with practical experience in AIT across 3 regions in China. Using a structured electronic questionnaire distributed via the Wenjuanxing platform, we systematically evaluated: physicians' basic information, the impact of the pandemic on AIT-related clinical decision-making, and the influence of COVID-19 vaccination on AIT. Data were analyzed using descriptive statistics, Pearson chi-square/Fisher exact tests, and multinomial logistic regression. Results: Among surveyed physicians, 70.5% maintained standard AIT initiation during the pandemic. Most physicians (64.9% for subcutaneous injections, 57% for sublingual administration) implemented a conservative 8- to 14-day interval between AIT and COVID-19 vaccination, exceeding the 7-day EAACI recommendation, with variations based on physician AIT experience ( Conclusion: This study documents how Chinese physicians adapted AIT practices during COVID-19. These clinician-developed strategies provide an applicable framework for maintaining AIT safety and efficacy during future public health crises while informing evidence-based guideline development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.